OpenLB
Open Library of Bioscience
Advanced Search
Fukushima journal of medical science
Jan 18, 2025;71 (1): 63-68.

Successful treatment of anti-signal recognition particle antibody-positive myositis with intravenous cyclophosphamide: A case report.

Jumpei Temmoku, Shuhei Yoshida, Kanae Tsuchihashi, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Nozomu Matsuda, Shuzo Sato, Kiyoshi Migita
Author Information
  1. Jumpei Temmoku: Department of Rheumatology, Fukushima Medical University School of Medicine.
  2. Shuhei Yoshida: Department of Rheumatology, Fukushima Medical University School of Medicine.
  3. Kanae Tsuchihashi: Department of Neurology, Fukushima Medical University School of Medicine.
  4. Yuya Sumichika: Department of Rheumatology, Fukushima Medical University School of Medicine.
  5. Kenji Saito: Department of Rheumatology, Fukushima Medical University School of Medicine.
  6. Haruki Matsumoto: Department of Rheumatology, Fukushima Medical University School of Medicine.
  7. Yuya Fujita: Department of Rheumatology, Fukushima Medical University School of Medicine.
  8. Naoki Matsuoka: Department of Rheumatology, Fukushima Medical University School of Medicine.
  9. Tomoyuki Asano: Department of Rheumatology, Fukushima Medical University School of Medicine.
  10. Nozomu Matsuda: Department of Neurology, Fukushima Medical University School of Medicine.
  11. Shuzo Sato: Department of Rheumatology, Fukushima Medical University School of Medicine.
  12. Kiyoshi Migita: Department of Rheumatology, Fukushima Medical University School of Medicine.
PMID: 39647862 DOI: 10.5387/fms.24-00013

Abstract

Myositis-specific autoantibodies play an important role on the disease phenotype of idiopathic inflammatory myopathies (IIMs). Anti-signal recognition particle (SRP) antibody-positive patients with IIMs may present with severe myopathy and highly elevated serum creatine kinase levels. These patients are often resistant to immunosuppressive therapy, but there is no established treatment strategy. A 51-year-old man referred to our department was diagnosed with IIM based on imaging and pathological findings. A high dose of corticosteroids followed by intravenous cyclophosphamide (IV-CY) treatment (750 mg three times) resulted in an improvement in clinical manifestations and functional outcomes, and recurrence did not occur. Our case suggests that IV-CY is an effective induction regimen for patients with anti-SRP antibody-positive IIMs.

Keywords

Idiopathic Inflammatory Myopathies Myositis-Specific Autoantibodies Signal Recognition Particle Antibodies.

References

  1. Curr Opin Rheumatol. 2016 Nov;28(6):619-24 [PMID: 27607340]
  2. Lancet Respir Med. 2023 Jan;11(1):45-54 [PMID: 36375479]
  3. Arthritis Care Res (Hoboken). 2010 Sep;62(9):1328-34 [PMID: 20506493]
  4. J Transl Autoimmun. 2022 Dec 15;6:100178 [PMID: 36589266]
  5. Semin Arthritis Rheum. 2022 Dec;57:152088 [PMID: 36116345]
  6. Front Immunol. 2022 Oct 13;13:1019972 [PMID: 36311711]
  7. Front Immunol. 2022 Sep 15;13:940122 [PMID: 36189221]
  8. Front Immunol. 2023 Sep 05;14:1177721 [PMID: 37731487]
  9. Arthritis Res Ther. 2012 Dec 28;14(6):230 [PMID: 23270751]
  10. Neurol Neuroimmunol Neuroinflamm. 2017 Jul 07;4(5):e381 [PMID: 28975138]
  11. Orphanet J Rare Dis. 2015 May 13;10:61 [PMID: 25963141]
  12. Rheumatology (Oxford). 2016 Jun;55(6):991-9 [PMID: 26888854]
  13. Front Immunol. 2022 Dec 12;13:1051609 [PMID: 36578492]
  14. Biomed Res Int. 2022 May 26;2022:8345737 [PMID: 35707391]
  15. Intern Med J. 2021 Jun;51(6):845-852 [PMID: 34155760]
  16. Eur J Intern Med. 2013 Oct;24(7):590-6 [PMID: 23528932]
  17. Rheumatology (Oxford). 2017 Jan;56(1):26-36 [PMID: 27121778]
  18. J Immunol. 2002 Dec 15;169(12):7127-34 [PMID: 12471150]
  19. Neuromuscul Disord. 2018 Jan;28(1):87-99 [PMID: 29221629]
  20. Semin Arthritis Rheum. 2023 Apr;59:152164 [PMID: 36773521]
  21. Arthritis Care Res (Hoboken). 2017 Feb;69(2):263-270 [PMID: 27111848]
  22. Front Neurol. 2016 May 20;7:64 [PMID: 27242652]

MeSH Term

Humans
Male
Middle Aged
Cyclophosphamide
Signal Recognition Particle
Myositis
Autoantibodies
Immunosuppressive Agents
Administration, Intravenous

Chemicals

Cyclophosphamide
Signal Recognition Particle
Autoantibodies
Immunosuppressive Agents
Case Reports Journal Article

Word Cloud

Created with Highcharts 10.0.0IIMsantibody-positivepatientstreatmentrecognitionparticleintravenousIV-CYcaseMyositis-specificautoantibodiesplayimportantrolediseasephenotypeidiopathicinflammatorymyopathiesAnti-signalSRPmaypresentseveremyopathyhighlyelevatedserumcreatinekinaselevelsoftenresistantimmunosuppressivetherapyestablishedstrategy51-year-oldmanreferreddepartmentdiagnosedIIMbasedimagingpathologicalfindingshighdosecorticosteroidsfollowedcyclophosphamide750mgthreetimesresultedimprovementclinicalmanifestationsfunctionaloutcomesrecurrenceoccursuggestseffectiveinductionregimenanti-SRPSuccessfulanti-signalmyositiscyclophosphamide:reportIdiopathicInflammatoryMyopathiesMyositis-SpecificAutoantibodiesSignalRecognitionParticleAntibodies

Similar Articles

Cited By